Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Leonard

Showing results (531-540 of 686) with videos related to

Pageof 69
Sort By:
British Journal of Haematology|May 27, 2009
A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphomaAndres Forero-Torres, John P Leonard, Anas Younes, et al.
Leukemia & Lymphoma|February 28, 2007
Dose-attenuated radioimmunotherapy with tositumomab and iodine 131 tositumomab in patients with recurrent non-Hodgkin's lymphoma (NHL) and extensive bone marrow involvementJodi V Mones, Morton Coleman, Lale Kostakoglu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 9, 2004
The radioisotope contributes significantly to the activity of radioimmunotherapyThomas A Davis, Mark S Kaminski, John P Leonard, et al.
The Lancet. Haematology|October 11, 2021
Venetoclax with dose-adjusted EPOCH-R as initial therapy for patients with aggressive B-cell lymphoma: a single-arm, multicentre, phase 1 studySarah C Rutherford, Jeremy S Abramson, Nancy L Bartlett, et al.
Journal of the American Chemical Society|August 22, 2017
Mg-Ion Battery Electrode: An Organic Solid's Herringbone Structure Squeezed upon Mg-Ion InsertionIsmael A Rodríguez-Pérez, Yifei Yuan, Clement Bommier, et al.
Molecular Medicine (Cambridge, Mass.)|May 5, 2015
Efficacy of Enzyme and Substrate Reduction Therapy with a Novel Antagonist of Glucosylceramide Synthase for Fabry DiseaseKaren M Ashe, Eva Budman, Dinesh S Bangari, et al.
Blood|December 15, 2007
A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignanciesNancy L Bartlett, Anas Younes, Matthew H Carabasi, et al.
The New England Journal of Medicine|November 5, 2015
Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell LymphomaJia Ruan, Peter Martin, Bijal Shah, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 8, 2016
CNS-accessible Inhibitor of Glucosylceramide Synthase for Substrate Reduction Therapy of Neuronopathic Gaucher DiseaseJohn Marshall, Ying Sun, Dinesh S Bangari, et al.
Human Molecular Genetics|May 8, 2012
Loss of GM3 synthase gene, but not sphingosine kinase 1, is protective against murine nephronophthisis-related polycystic kidney diseaseThomas A Natoli, Hervé Husson, Kelly A Rogers, et al.
Pageof 69

Showing results (531-540 of 686) with videos related to

Sort By:
Pageof 69
British Journal of Haematology|May 27, 2009
A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphomaAndres Forero-Torres, John P Leonard, Anas Younes, et al.
Leukemia & Lymphoma|February 28, 2007
Dose-attenuated radioimmunotherapy with tositumomab and iodine 131 tositumomab in patients with recurrent non-Hodgkin's lymphoma (NHL) and extensive bone marrow involvementJodi V Mones, Morton Coleman, Lale Kostakoglu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 9, 2004
The radioisotope contributes significantly to the activity of radioimmunotherapyThomas A Davis, Mark S Kaminski, John P Leonard, et al.
The Lancet. Haematology|October 11, 2021
Venetoclax with dose-adjusted EPOCH-R as initial therapy for patients with aggressive B-cell lymphoma: a single-arm, multicentre, phase 1 studySarah C Rutherford, Jeremy S Abramson, Nancy L Bartlett, et al.
Journal of the American Chemical Society|August 22, 2017
Mg-Ion Battery Electrode: An Organic Solid's Herringbone Structure Squeezed upon Mg-Ion InsertionIsmael A Rodríguez-Pérez, Yifei Yuan, Clement Bommier, et al.
Molecular Medicine (Cambridge, Mass.)|May 5, 2015
Efficacy of Enzyme and Substrate Reduction Therapy with a Novel Antagonist of Glucosylceramide Synthase for Fabry DiseaseKaren M Ashe, Eva Budman, Dinesh S Bangari, et al.
Blood|December 15, 2007
A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignanciesNancy L Bartlett, Anas Younes, Matthew H Carabasi, et al.
The New England Journal of Medicine|November 5, 2015
Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell LymphomaJia Ruan, Peter Martin, Bijal Shah, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 8, 2016
CNS-accessible Inhibitor of Glucosylceramide Synthase for Substrate Reduction Therapy of Neuronopathic Gaucher DiseaseJohn Marshall, Ying Sun, Dinesh S Bangari, et al.
Human Molecular Genetics|May 8, 2012
Loss of GM3 synthase gene, but not sphingosine kinase 1, is protective against murine nephronophthisis-related polycystic kidney diseaseThomas A Natoli, Hervé Husson, Kelly A Rogers, et al.
Pageof 69